FluoGuide Valuation

Is FLUO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FLUO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: FLUO (SEK34.25) is trading below our estimate of fair value (SEK235.71)

Significantly Below Fair Value: FLUO is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for FLUO?

Key metric: As FLUO barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for FLUO. This is calculated by dividing FLUO's market cap by their current book value.
What is FLUO's PB Ratio?
PB Ratio8.2x
BookDKK 36.98m
Market CapDKK 302.29m

Price to Book Ratio vs Peers

How does FLUO's PB Ratio compare to its peers?

The above table shows the PB ratio for FLUO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.5x
HAMLET B Hamlet BioPharma
8.1xn/aSEK 439.5m
ONCO Oncopeptides
2.4x35.8%SEK 330.5m
ISOFOL Isofol Medical
5.2xn/aSEK 474.9m
MVIR Medivir
2.1x43.1%SEK 304.0m
FLUO FluoGuide
8.2x49.9%SEK 466.1m

Price-To-Book vs Peers: FLUO is expensive based on its Price-To-Book Ratio (8.2x) compared to the peer average (4.5x).


Price to Book Ratio vs Industry

How does FLUO's PB Ratio compare vs other companies in the SE Biotechs Industry?

8 CompaniesPrice / BookEstimated GrowthMarket Cap
COMBI CombiGene
0.6xn/aUS$4.59m
EXPRS2 ExpreS2ion Biotech Holding
0.6x-11.9%US$3.66m
SCOL Scandion Oncology
0.5x69.7%US$1.52m
DIABIO Diagonal Bio
0.5xn/aUS$1.23m
FLUO 8.2xIndustry Avg. 2.4xNo. of Companies11PB02.44.87.29.612+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: FLUO is expensive based on its Price-To-Book Ratio (8.2x) compared to the Swedish Biotechs industry average (2.4x).


Price to Book Ratio vs Fair Ratio

What is FLUO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FLUO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio8.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate FLUO's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies